Strategic Expansion Eyenovia is actively exploring partnerships and corporate development moves, including potential combination with Betaliq to form a publicly listed eye care company, indicating a readiness to pursue strategic M&A and co-venture opportunities that can open up new market segments and funding channels.

Digital Asset Growth The company is expanding its digital asset program with a PIPE financing, new CIO appointment, and treasury strategy leadership, signaling an opportunity to position sales around innovative technology partnerships, crypto treasury services, and blockchain-enabled service offerings for pharma finance and asset management.

Device and Drug Synergy Eyenovia focuses on the Optejet device for presbyopia and pediatric progressive myopia, presenting a selling point for adjacent device-drug combination opportunities, licensing talks, and co-development deals that leverage Optejet for additional ophthalmic indications.

Commercial Leadership Changes Recent leadership change in commercial operations and added strategic advisory resources imply potential for refreshed go-to-market strategies, enabling sales teams to align with new leadership objectives, channel strategies, and improved field execution.

Investment and Partnerships With significant financing, advisory appointments, and partnerships in crypto and asset management, there is scope to pitch financial and technology collaboration services, as well as joint ventures that combine Ophthalmic tech with innovative financing and digital infrastructure.